Equities

Sanara Medtech Inc

SMTI:NAQ

Sanara Medtech Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)37.76
  • Today's Change0.44 / 1.18%
  • Shares traded32.48k
  • 1 Year change+16.47%
  • Beta1.5846
Data delayed at least 15 minutes, as of Nov 22 2024 19:46 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 21-Nov-24
Select bar for recommendation details.
Recommendations21-Nov-24
Buy0
Outperform1
Hold0
Sell0
Strong Sell0

Share price forecast in USD

The one analyst offering a 12 month price target expects Sanara Medtech Inc share price to rise to 44.00 in the next year from the last price of 37.32.
High17.9%44.00
Med17.9%44.00
Low17.9%44.00

Earnings history & estimates in USD

On Nov 12, 2024, Sanara Medtech Inc reported 3rd quarter 2024 losses of -0.34 per share. This result exceeded the -0.62 consensus loss of the one analyst covering the company and under-performed last year's 3rd quarter results by -0.21.
The next earnings announcement is expected on Mar 24, 2025.
Average growth rate-150.31%
Sanara Medtech Inc reported annual 2023 losses of -0.52 per share on Mar 25, 2024.
Average growth rate+29.84%
More ▼

Revenue history & estimates in USD

Sanara MedTech Inc. had 3rd quarter 2024 revenues of 21.67m. This bettered the 20.70m estimate of the one analyst covering the company. This was 39.62% above the prior year's 3rd quarter results.
Average growth rate+7.86%
Sanara MedTech Inc. had revenues for the full year 2023 of 64.99m. This was 41.77% above the prior year's results.
Average growth rate+9,478.78%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.